By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics said today that it has signed up the biomedical distributor Dateks to market its colorectal cancer test in Turkey.

Epigenomics said that Dateks will market the Epi proColon, a DNA methylation-based test that detects colorectal cancer in blood plasma by identifying the Septin 9 biomarker.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.